On this page

calcipotriene

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
calcipotriene
Generic name
calcipotriene
Dosage form
Cream
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Prasco Laboratories
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
3
Packages
6
Data completeness
77% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Calcipotriene 50 ug/g 198373 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
9

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Vitamin D Analog [EPC] EPC All 10 members
Vitamin D [CS] CS 5 members — no class page

Regulatory status

Source: Drugs@FDANDC Directory
Application number
205772
Application type
ANDA · Abbreviated New Drug Application
Approval date
June 9, 2015
Sponsor
GLENMARK SPECLT
Products on application
1
Submissions recorded
2
Products approved under application 205772.
Product Trade name Form Strength Ingredient Status TE Flags
205772-001 CALCIPOTRIENE CREAM CALCIPOTRIENE Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 205772.
Type No. Action Status Date Review
Supplement 7 Labeling Approved April 17, 2026 Standard
Original application 1 Approved June 9, 2015 Standard

Review documents

  • 0 · Original application · June 11, 2015

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251027). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20251027 HUMAN PRESCRIPTION DRUG · 20240624 HUMAN PRESCRIPTION DRUG · 20221212

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Calcipotriene Cream, 0.005%, is indicated for the treatment of plaque psoriasis. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Apply a thin layer of Calcipotriene Cream to the affected skin twice daily and rub in gently and completely. The safety and efficacy of Calcipotriene Cream have been demonstrated in patients treated for eight weeks.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Calcipotriene Cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. It should not be used by patients with demonstrated hypercalcemia or evidence of vitamin D toxicity. Calcipotriene Cream should not be used on the face.

WARNINGS Contact dermatitis, including allergic contact dermatitis, has been observed with the use of Calcipotriene Cream.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Clinical Trials Experience In controlled clinical trials, the most frequent adverse experiences reported for calcipotriene cream, 0.005% were cases of skin irritation, which occurred in approximately 10 to 15% of patients. Rash, pruritus, dermatitis and worsening of psoriasis were reported in 1 to 10% of patients. Postmarketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions associated with the use of calcipotriene cream have been identified post-approval: contact dermatitis, including allergic contact dermatitis. To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Calcipotriene Cream USP, 0.005% contains calcipotriene, USP, a synthetic vitamin D 3 derivative, for topical dermatological use. Chemically, calcipotriene, USP is (5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1α,3β,24-triol, with the empirical formula C 27 H 40 O 3 , a molecular weight of 412.62 and the following structural formula: Calcipotriene, USP is a white or almost white crystalline powder. Calcipotriene Cream USP, 0.005% contains 50 mcg/g anhydrous calcipotriene, USP in a cream base of benzyl alcohol, cetostearyl alcohol, ceteth-20, disodium hydrogen phosphate dihydrate, glycerin, medium chain triglycerides, mineral oil, monosodium phosphate monohydrate, purified water and white petrolatum. Y:\Regulatory Affairs 2\ANDAs\Calcipotriene cream (205772)\_Misc\Northstar\structure.jpg

OVERDOSAGE Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of topical calcipotriene. If elevation in serum calcium should occur, discontinue treatment until normal calcium levels are restored. (See PRECAUTIONS .)

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Calcipotriene Cream, 0.005% is available in: 60 gram aluminum tubes (NDC 66993-877-61) 120 gram aluminum tubes (NDC 66993-877-78)

Adverse event reports

Source: openFDA FAERS
6,726
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: CALCIPOTRIENE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class II March 15, 2017 LEO PHARMA INC Incorrect/Undeclared excipients: inadvertent omission of a drug excipient from the the Authorized Generic label and also a warning regarding contact dermatitis from the brand product labeling not being incorporated into the Authorized Generic labeling. Terminated

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
68462-501-65 68462-501 Glenmark Pharmaceuticals Inc.,USA 1 TUBE in 1 CARTON (68462-501-65) / 60 g in 1 TUBE June 10, 2015
68462-501-66 68462-501 Glenmark Pharmaceuticals Inc.,USA 1 TUBE in 1 CARTON (68462-501-66) / 120 g in 1 TUBE June 10, 2015
16714-763-01 16714-763 Northstar Rx LLC 1 TUBE in 1 CARTON (16714-763-01) / 60 g in 1 TUBE May 1, 2018
16714-763-02 16714-763 Northstar Rx LLC 1 TUBE in 1 CARTON (16714-763-02) / 120 g in 1 TUBE May 1, 2018
66993-877-61 66993-877 Prasco Laboratories 1 TUBE in 1 CARTON (66993-877-61) / 60 g in 1 TUBE October 1, 1996
66993-877-78 66993-877 Prasco Laboratories 1 TUBE in 1 CARTON (66993-877-78) / 120 g in 1 TUBE October 1, 1996
68462-501 68462-501 Glenmark Pharmaceuticals Inc.,USA — June 10, 2015
16714-763 16714-763 Northstar Rx LLC — June 1, 2015
66993-877 66993-877 Prasco Laboratories — October 1, 1996

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records

Generated September 25, 2026 · 13 sections on this page.